A Multicenter Randomized Phase II Study of Docetaxel/Carboplatin Versus Docetaxel/Pegylated Liposomal Doxorubicin as Second Line Treatment in Patients With Platinum Sensitive Disease.
Phase of Trial: Phase II
Latest Information Update: 30 Sep 2015
At a glance
- Drugs Docetaxel (Primary) ; Doxorubicin liposomal (Primary) ; Carboplatin
- Indications Ovarian cancer
- Focus Therapeutic Use
- 30 Sep 2015 Status changed from withdrawn prior to enrolment to discontinued as reported by ClinicalTrials.gov.
- 20 May 2011 Planned end date changed from 1 Feb 2011 to 1 Mar 2011 as reported by ClinicalTrials.gov.
- 20 May 2011 Status changed from recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.